Bharat Biotech, which is manufacturing COVID-19 vaccine Covaxin, on May 20 announced ramping up of additional manufacturing capacities for the vaccine in India.
The company, in a statement said that it is ramping up the facilities at Chiron Behring Vaccines, Ankleshwar Gujarat, a wholly-owned subsidiary of Bharat Biotech.
Bharat Biotech plans to produce 20 crore doses of Covaxin per annum in the good manufacturing practice (GMP) facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety.
Product availability at Ankleshwar to commence from Q4 of 2021.
Bharat Biotech had already deployed multiple production lines at its Hyderabad and Bengaluru campuses, adding Chiron Behring to this line up of high containment BSL rated GMP facilities that are required to manufacture Covaxin.
This effectively takes the volumes upto 100 crore doses per annum, with its own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety.